Immunic, Inc.

Equities

IMUX

US4525EP1011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
1.245 ^USD	-0.40%		-1.97%	-17.00%

May. 08	Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08	Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 08, 2024 at 07:20 am EDT

Immunic, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 29.58 million compared to USD 25.27 million a year ago. Basic loss per share from continuing operations was USD 0.3 compared to USD 0.58 a year ago.

Latest news about Immunic, Inc.

Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation	Apr. 30	CI
Transcript : Immunic, Inc. - Special Call	Apr. 09
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium	Mar. 21	MT
Wedbush Adjusts Immunic's PT to $4 From $7 on Increased Sharecount From First Tranche of Private Placemebt, Keeps Outperform Rating	Feb. 23	MT
Transcript : Immunic, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Immunic Launches 3-Tranche Private Placement of Up to $240 Million; Shares Rise	Jan. 05	MT
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Investors Await Jobs Data as US Futures Trend Lower in Friday's Premarket	Jan. 05	MT
Top Premarket Gainers	Jan. 05	MT
Immunic Files $250 Million Mixed-Securities Shelf Registration	Nov. 22	MT
Immunic Receives Notice of Allowance From US Patent Office for Dosing Regimens for Treating Multiple Sclerosis	Nov. 21	MT
Transcript : Immunic, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
North American Morning Briefing : Caution Dominates Ahead of CPI Print	Nov. 14	DJ
Immunic, Inc. Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis Vidofludimus and Its Salts	Nov. 02	CI
Immunic Says Early-Stage Trial Shows 'Positive Effects' of Celiac Disease Drug Over Placebo	23-10-16	MT
Immunic, Inc. Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023	23-10-15	CI
Wedbush Adjusts Price Target on Immunic to $7 From $5, Maintains Outperform Rating	23-10-10	MT
Transcript : Immunic, Inc. - Special Call	23-10-10
Top Premarket Gainers	23-10-10	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	23-10-10	DJ
Immunic Says Phase 2 Trial Reinforces Vidofludimus Calcium's Neuroprotective Potential; Shares Soar Premarket	23-10-10	MT

Chart Immunic, Inc.

Duration

Period

More charts

Company Profile

Immunic, Inc. is a biotechnology company. The Company is focused on developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The Companyâs s lead development program, vidofludimus calcium (IMU-838), is in phase III and phase II clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase II clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease. IMU-381 is in preclinical testing, a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-11 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.245 USD

Average target price

11.5 USD

Spread / Average Target

+823.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
IMMUNIC, INC.	-17.00%	112M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-2.62%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs